Thank you very much, Mr. Gagnon.
Ms. Roy, you said you were concerned that with mandatory reporting of adverse drug reactions, there would be too much information. We've heard that from other witnesses as well; perhaps it's quantity not necessarily enhancing quality. Conversely, would there not also be a problem with not getting enough information to ensure it is adequate to suggest changes should take place, and that there's enough of a sampling of people? Is that also not a challenge, if it's limited?